Show simple item record

dc.contributor.authorPritchard-Jones, K
dc.date.accessioned2018-09-17T15:14:13Z
dc.date.issued2002-09
dc.identifier3
dc.identifier.citationARCHIVES OF DISEASE IN CHILDHOOD, 2002, 87 pp. 241 - 244
dc.identifier.issn0003-9888
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2725
dc.identifier.doi10.1136/adc.87.3.241
dc.description.abstractWilms tumour is one of the success stories of paediatric oncology with long term survival approaching 90% in localised disease and over 70% for metastatic disease. Although appearing relatively simple compared to other cancer treatment regimens, successful treatment of Wilms tumour requires meticulous attention to correct staging of the tumour and good communication between the paediatric surgeon, pathologist and oncologist. The controversy of whether pre-operative chemotherapy results in a reduced overall burden of treatment compared to immediate nephrectomy has been addressed by the recently closed UKW3 randomised trial. Challenges remain in identification of histological and molecular risk factors for stratification of treatment intensity to allow safe reduction in therapy and avoidance of late sequelae for the majority while leading to increased biological insights and ultimately hovel therapies for the minority of high risk tumours. Genetic predisposition to Wilms tumour is conferred by several genes, some of which cause malformation rather than cancer and may be of low penetrance. The proportion of children with heritable disease is uncertain and there remains a need to collect data on the need for screening, in this susceptible population.
dc.format.extent241 - 244
dc.languageeng
dc.language.isoeng
dc.publisherBRITISH MED JOURNAL PUBL GROUP
dc.titleControversies and advances in the management of Wilms’ tumour
dc.typeJournal Article
rioxxterms.versionofrecord10.1136/adc.87.3.241
rioxxterms.licenseref.startdate2002-09
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfARCHIVES OF DISEASE IN CHILDHOOD
pubs.notesaffiliation: Pritchard-Jones, K (Reprint Author), Royal Marsden Hosp, Canc Res Inst, Sect Paediat Oncol, Downs Rd, Sutton, Surrey, England. Royal Marsden Hosp, Canc Res Inst, Sect Paediat Oncol, Sutton, Surrey, England. keywords-plus: BECKWITH-WIEDEMANN-SYNDROME; DENYS-DRASH; GENE FWT1; WT1 GENE; MUTATIONS; CHILDREN; RISK; HEMIHYPERTROPHY; ANIRIDIA; DURATION research-areas: Pediatrics web-of-science-categories: Pediatrics researcherid-numbers: Pritchard-Jones, Kathy/F-4286-2014 orcid-numbers: Pritchard-Jones, Kathy/0000-0002-2384-9475 number-of-cited-references: 28 times-cited: 46 usage-count-last-180-days: 0 usage-count-since-2013: 0 journal-iso: Arch. Dis. Child. doc-delivery-number: 589QC unique-id: ISI:000177770700024 oa: gold_or_bronze da: 2018-09-17
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR
pubs.volume87
pubs.embargo.termsNot known
dc.contributor.icrauthorPritchard-Jones, Kathyen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record